GTG Further Expands Its Licensing Program in Europe

This appointment follows similar recent announcements concerningthe appointment of PatentBridge LLC on the U.S. west coast, DicksteinShapiro Morin & Oshinsky LLP on the U.S. east coast and SJ Berwin inLondon.

This latest appointment follows market research by GTG whichidentified a significant number of biotechnology firms based inGermany, Austria and Switzerland, who would benefit from taking alicense to the GTG non-coding patents.

About the GTG non-coding patents. The GTG non-coding patents arerelevant to the current and intended activities of many biotechnologycompanies and research teams world-wide. The patents fall into twofamilies -- non-coding analysis and non-coding mapping, and thepatents are issued in all 24 countries in which they were originallyfiled. GTG has successfully settled six legal challenges to thepatents on terms favourable to GTG, and GTG is now focussed onmaximizing its licensing opportunities during the next 10 years,before these patents expire. GTG has so far approved 31 licenses tothese patents, 26 of them to commercial entities, for a totalconsideration of approximately A$53 million. GTG has meanwhileidentified numerous additional parties who would benefit from alicense to the GTG non-coding patents. Accordingly, GTG continues toapply increasing resources to this global out-licensing program.

About Doralt Seist Csoklich. This firm provides legal counsellingacross a wide range of business activities, including trans-bordertransactions. One partner, Dr. Christoph Leitgeb, has both a legaldegree and also a PhD in molecular genetics, and with his extensiveexperience in patent law and licensing, is expected to take an activerole in assisting the GTG licensing program in the German speakingcountries.

About Genetic Technologies Limited

Genetic Technologies was an early pioneer in recognizing importantnew applications for "non-coding" DNA (DeoxyriboNucleic Acid). TheCompany has since been granted patents in 24 countries around theworld, securing intellectual property rights for particular uses ofnon-coding DNA in genetic analysis and gene mapping across all genesin all multicellular species. Its three-pronged business strategyincludes: 1) the global commercialization of its patents through anactive licensing program; 2) the expansion of its dominant commercialgenetic testing business in Australia; and, 3) the commercializationof its various research and development projects aimed at generatingfurther intellectual property of global commercial significance.

This announcement may contain forward-looking statements withinthe meaning of Section 27A of the U.S. Securities Act of 1933 andSection 21E of the U.S. Securities Exchange Act of 1934 with respectto the financial condition, results and businessachievements/performance of Genetic Technologies Limited and certainof the plans and objectives of its management. These statements arestatements that are not historical facts. Words such as "should","expects", "anticipates", "estimates", "believes" or similarexpressions, as they relate to Genetic Technologies Limited, areintended to identify forward-looking statements. By their nature,forward-looking statements involve risk and uncertainty because theyreflect Genetic Technologies' current expectations and assumptions asto future events and circumstances that may not prove accurate. Thereis no guarantee that the expected events, trends or results willactually occur. Any changes in such assumptions or expectations couldcause actual results to differ materially from current expectations.